Trial · NCT00528606
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection | AA4500 0.58 mg | 64 | Percentage of Joints | ||
| Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection | Placebo | 6.8 | Percentage of Joints | ||
| Clinical Improvement After the Last Injection | AA4500 0.58 mg | 84.7 | Percentage of Joints | ||
| Clinical Improvement After the Last Injection | Placebo | 11.7 | Percentage of Joints | ||
| Percent Reduction From Baseline Contracture After the Last Injection | AA4500 0.58 mg | 79.3 | Standard Deviation 32.58 | Percent reduction from baseline | |
| Percent Reduction From Baseline Contracture After the Last Injection | Placebo | 8.6 | Standard Deviation 30.78 | Percent reduction from baseline | |
| Change From Baseline Range of Motion After the Last Injection | AA4500 0.58 mg | 36.70 | Standard Deviation 21.01 | degrees | |
| Change From Baseline Range of Motion After the Last Injection | Placebo | 4.0 | Standard Deviation 14.77 | degrees | |
| Time to First Achieve Success After the Last Injection | AA4500 0.58 mg | Injection 1, Day 1 | 12.8 | percentage of joints | |
| Time to First Achieve Success After the Last Injection | Placebo | Injection 1, Day 1 | 0.0 | percentage of joints | |
| Time to First Achieve Success After the Last Injection | AA4500 0.58 mg | Injection 1, Day 7 | 12.3 | percentage of joints | |
| Time to First Achieve Success After the Last Injection | Placebo | Injection 1, Day 7 | 0.0 | percentage of joints | |
| Time to First Achieve Success After the Last Injection | AA4500 0.58 mg | Injection 1, Day 30 | 14.3 | percentage of joints | |
| Time to First Achieve Success After the Last Injection | Placebo | Injection 1, Day 30 | 1.0 | percentage of joints | |
| Time to First Achieve Success After the Last Injection | AA4500 0.58 mg | Injection 2, Day 0 | 0.5 | percentage of joints | |
| Time to First Achieve Success After the Last Injection | Placebo | Injection 2, Day 0 | 0.0 | percentage of joints | |
| Time to First Achieve Success After the Last Injection | AA4500 0.58 mg | Injection 2, Day 1 | 4.9 | percentage of joints | |
| Time to First Achieve Success After the Last Injection | Placebo | Injection 2, Day 1 | 0.0 | percentage of joints | |
| Time to First Achieve Success After the Last Injection | AA4500 0.58 mg | Injection 2, Day 7 | 5.4 | percentage of joints | |
| Time to First Achieve Success After the Last Injection | Placebo | Injection 2, Day 7 | 0.0 | percentage of joints |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00528606/results